Detail akcie Phio Pharma Rg online

Business Summary: Phio Pharmaceuticals Corp. is a clinical-stage biotechnology company. The Company's INTASYL self-delivering RNAi technology platform is designed to make immune cells more effective in killing tumor cells. It is developing therapeutics that are designed to leverage INTASYL to target specific proteins that reduce the body's ability to fight cancer, without the need for specialized formulations or drug delivery systems. The Company's pipeline is focused on the treatment of cutaneous Squamous Cell Carcinoma (cSCC) and melanoma. Its product pipeline includes PH-762 and PH-894. PH-762 is an INTASYL compound designed to reduce the expression of cell death protein 1 (PD-1). PD-1 is a protein that inhibits T cells’ ability to kill cancer cells and is a clinically validated target in immunotherapy. PH-894 is an INTASYL compound that is designed to silence BRD4, a protein that controls gene expression in both T cells and tumor cells, thereby affecting the immune system as well as the tumor.
Financial Summary: BRIEF: For the nine months ended 30 September 2025, Phio Pharmaceuticals Corp revenues was not reported. Net loss increased 15% to $6.3M. Higher net loss reflects PHARMACEUTICAL PREPARATIONS segment loss increase of 91% to $6.7M. Basic Earnings per Share excluding Extraordinary Items increased from -$9.39 to -$1.30.